These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
675 related articles for article (PubMed ID: 30487789)
1. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M Front Immunol; 2018; 9():2329. PubMed ID: 30487789 [TBL] [Abstract][Full Text] [Related]
2. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB Front Immunol; 2021; 12():715704. PubMed ID: 34456924 [TBL] [Abstract][Full Text] [Related]
3. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series. Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767 [TBL] [Abstract][Full Text] [Related]
4. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Noris M; Donadelli R; Remuzzi G Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306 [TBL] [Abstract][Full Text] [Related]
5. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy. Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ Front Immunol; 2019; 10():1350. PubMed ID: 31263464 [TBL] [Abstract][Full Text] [Related]
6. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ; J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465 [TBL] [Abstract][Full Text] [Related]
7. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516 [TBL] [Abstract][Full Text] [Related]
8. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854 [TBL] [Abstract][Full Text] [Related]
9. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. Garam N; Prohászka Z; Szilágyi Á; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik-Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Romana Rysava ; Reiterova J; Saraga M; Tomáš Seeman ; Zieg J; Sládková E; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Csuka D Orphanet J Rare Dis; 2019 Nov; 14(1):247. PubMed ID: 31703608 [TBL] [Abstract][Full Text] [Related]
10. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476 [TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort. Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601 [TBL] [Abstract][Full Text] [Related]
12. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535 [TBL] [Abstract][Full Text] [Related]
13. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF. Tanuma Y; Ohi H; Hatano M Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128 [TBL] [Abstract][Full Text] [Related]
14. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III. West CD; McAdams AJ Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679 [TBL] [Abstract][Full Text] [Related]
15. Membranoproliferative glomerulonephritis type III: association of glomerular deposits with circulating nephritic factor-stabilized convertase. West CD; McAdams AJ Am J Kidney Dis; 1998 Jul; 32(1):56-63. PubMed ID: 9669425 [TBL] [Abstract][Full Text] [Related]
16. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation. Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G; Nephron; 2020; 144(4):195-203. PubMed ID: 32050203 [TBL] [Abstract][Full Text] [Related]
17. Causes of alternative pathway dysregulation in dense deposit disease. Zhang Y; Meyer NC; Wang K; Nishimura C; Frees K; Jones M; Katz LM; Sethi S; Smith RJ Clin J Am Soc Nephrol; 2012 Feb; 7(2):265-74. PubMed ID: 22223606 [TBL] [Abstract][Full Text] [Related]
18. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G; Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851 [TBL] [Abstract][Full Text] [Related]
19. FHR-5 Serum Levels and Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D Front Immunol; 2021; 12():720183. PubMed ID: 34566977 [TBL] [Abstract][Full Text] [Related]
20. Modeling C3 glomerulopathies: C3 convertase regulation on an extracellular matrix surface. Pisarenka S; Meyer NC; Xiao X; Goodfellow R; Nester CM; Zhang Y; Smith RJH Front Immunol; 2022; 13():1073802. PubMed ID: 36846022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]